Noninvasive Metabolic Profiling for Painless Diagnosis of Human Diseases and Disorders

Mal, Mainak

doi:10.4155/fsoa-2015-0014

Cited by 19 publications

(18 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolome analysis of blood and urine samples from CRC patients were performed, and several studies reported relevant biomarkers for CRC[ 166 - 168 ]. However, the transient localization of faeces in the colon and rectum makes it an ideal matrix for gaining information about the health and pathological state of the colon and rectum, and thus for colorectal cancer diagnosis[ 169 ]. Faecal samples consist of a diverse range of endogenous metabolites including tumour cell metabolites and gut microbiota metabolites[ 169 ].…”

Section: Microbial Signatures In Crcmentioning

confidence: 99%

Microbial markers in colorectal cancer detection and/or prognosis

Villéger¹,

Lopès²,

Véziant³

et al. 2018

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second leading cause of cancer worldwide. CRC is still associated with a poor prognosis among patients with advanced disease. On the contrary, due to its slow progression from detectable precancerous lesions, the prognosis for patients with early stages of CRC is encouraging. While most robust methods are invasive and costly, actual patient-friendly screening methods for CRC suffer of lack of sensitivity and specificity. Therefore, the development of sensitive, non-invasive and cost-effective methods for CRC detection and prognosis are necessary for increasing the chances of a cure. Beyond its beneficial functions for the host, increasing evidence suggests that the intestinal microbiota is a key factor associated with carcinogenesis. Many clinical studies have reported a disruption in the gut microbiota balance and an alteration in the faecal metabolome of CRC patients, suggesting the potential use of a microbial-based test as a non-invasive diagnostic and/or prognostic tool for CRC screening. This review aims to discuss the microbial signatures associated with CRC known to date, including dysbiosis and faecal metabolome alterations, and the potential use of microbial variation markers for non-invasive early diagnosis and/or prognostic assessment of CRC and advanced adenomas. We will finally discuss the possible use of these markers as predicators for treatment response and their limitations.

show abstract

Section: Microbial Signatures In Crcmentioning

confidence: 99%

Microbial markers in colorectal cancer detection and/or prognosis

Villéger¹,

Lopès²,

Véziant³

et al. 2018

WJG

View full text Add to dashboard Cite

show abstract

“…A cancer biomarker can be broadly defined as an objectively measurable parameter characterizing: (i) a malignant process or (ii) a pharmacological response to therapy. Biomarkers can exist in the form of DNA, RNA, or protein molecules [3], although emerging metabolic approaches are enabling candidate cancer biomarker discovery of various metabolites in both the preclinical [5,6] and clinical setting [7][8][9]. Historically, the first cancer biomarkers, tumor specific antigen carcinoembryonic antigen (CEA), and urinary Bence Jones protein were identified in colon carcinoma by the research group of Gold and Freedman [10,11].…”

Section: Cancer Biomarkersmentioning

confidence: 99%

Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies

Umelo

Costanza

Castronovo

2018

Cancer Metastasis Rev

View full text Add to dashboard Cite

The discovery of biomarkers able to detect cancer at an early stage, to evaluate its aggressiveness, and to predict the response to therapy remains a major challenge in clinical oncology and precision medicine. In this review, we summarize recent achievements in the discovery and development of cancer biomarkers. We also highlight emerging innovative methods in biomarker discovery and provide insights into the challenges faced in their evaluation and validation.

show abstract

“…The use of non-invasive or minimally invasive methods for diagnosing or predicting the onset of disease or inflammation in real-time or categorising metabolic state patient-side is revolutionising human medicine (Mal 2016). New rapid and precise technologies for genomic, transcriptomic and metabolomic testing are constantly being developed and improved on.…”

Section: Introductionmentioning

confidence: 99%

The frontiers of biomedical science and its application to animal science in addressing the major challenges facing Australasian dairy farming

et al. 2020

View full text Add to dashboard Cite

Extraordinary advances are occurring in biomedical science that may revolutionise how we approach health and disease. Many have applications in the dairy industry. We have described one particular area of extracellular vesicles that have already proven to be of interest in diagnostics and prognostics for fertility and assessment of 'transition' cows (i.e. evaluation of the problems related to the risk of clinical diseases in dairy cows, such as mastitis and milk fever, during transition period). The addition of measurements of circulating RNA and DNA may prove of value in identifying dairy cows with higher risks of clinical diseases and potentially poor fertility. We describe the exciting opportunity provided by the possibility of generating exosomes to order as therapeutic agents to potentially enhance fertility. The even more radical concept of using exosomes to deliver a CRISPR-linked gene editing function is presented. Undoubtedly, the use of biomedical advances to assist the dairy industry is an obvious and practical approach that has significant merit.

show abstract

Noninvasive Metabolic Profiling for Painless Diagnosis of Human Diseases and Disorders

Cited by 19 publications

References 108 publications

Microbial markers in colorectal cancer detection and/or prognosis

Microbial markers in colorectal cancer detection and/or prognosis

Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies

The frontiers of biomedical science and its application to animal science in addressing the major challenges facing Australasian dairy farming

Contact Info

Product

Resources

About